PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “ANTITHROMBIN”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 685 records · Page 38Linked to original sources

Inhibition of human activated Factor X by antithrombin III and alpha 1-proteinase inhibitor in human plasma.

The inhibition of activated human Factor X by human plasma protease inhibitors was investigated in both purified and plasma systems. In the former, antithrombin III, alpha 1-proteinase inhibitor, and alpha 2-macroglobulin, at normal plasma concentrations, markedly inhibited activated Factor X. Significant inhibition by alpha 2-antiplasmin, however, was only achieved when present at 40 times its plasma concentration. The relative rates of inhibition of activated Factor X coagulant activity in normal human plasma, antithrombin III-deficient plasma, and alpha 1-proteinase inhibitor-deficient plasma were 1.0, 0.63, and 0.75, respectively. From these relative rates of inhibition and their measured concentrations in the 3 plasmas, it was calculated that antithrombin III, alpha 1-proteinase inhibitor, and alpha 2-macroglobulin contribute 53, 35, and 12%, respectively, to the inhibition of activated Factor X in normal human plasma. Using 125I-labeled activated Factor X and a combination of sodium dodecyl sulfate disc gel electrophoresis and immunoadsorption, it was then demonstrated that antithrombin III accounted for 45-55%, alpha 1-proteinase inhibitor, 35-40%, and alpha 2-macroglobulin, 10-15% of the inhibition of the labeled protease in normal human plasma. The values obtained with the deficient plasmas are consistent with the distribution of activated Factor X-inhibitor complexes in normal human plasma. These data show by two independent techniques, one measuring coagulant activity and the other 125I-labeled activated Factor X-inhibitor complexes, that both antithrombin III and alpha 1-proteinase inhibitor are the major inhibitors of activated Factor X in normal human plasma.

Antithrombin III↗

Prophylactic and therapeutic use of anticoagulants in inherited antithrombin III deficiency.

A family with a pronounced history of venous thrombotic disease is described. Several members were found to have reduced antithrombin III levels. Heparin cofactor activity was reduced in the antithrombin III-deficient plasma. The proposita, who presented with bilateral iliofemoral vein thrombosis early in pregnancy, was treated initially with heparin, and after the 12th week of pregnancy was maintained on oral anticoagulants until she was 38 weeks pregnant. Heparin was then given and continued throughout the delivery period and for 10 days postpartum with no evidence of recurrent thrombosis. The effect of infusing 5 units of fresh frozen plasma on the antithrombin III level and the response to heparin were minimal and short-lived. Oral anticoagulatns produced a rise in the antithrombin III level. These results demonstrate the importance of maintaining antithrombin III-deficient subjects on long-term oral anticoagulant therapy.

Adult↗

Human hepatoma cells secrete single chain factor X, prothrombin, and antithrombin III.

The human hepatoma cell line, Hep G2, was analyzed for the ability to synthesize and secrete several coagulation proteins. Using specific radioimmunoassays, factor X, prothrombin, and antithrombin III were present in 8-day culture supernatants at 62, 405, and 1,220 ng/mL, respectively. Factor IX was not detected, either in supernatants or in cell extracts. Intrinsically labeled factor X was secreted as a single-chain polypeptide of 66,000 daltons, as measured by sodium dodecylsulfate-polyacrylamide gels under nonreduced and reduced conditions. Immunoblots of Hep G2 supernatants and normal human plasma also indicate the presence of single-chain factor X. These findings support the hypothesis of a postsecretion proteolytic cleavage of factor X into the two-chain form. Prothrombin and antithrombin represented their plasma protein counterparts structurally, with molecular weights of 73,000 and 61,000, respectively. Secreted factor X, prothrombin, and antithrombin III were biologically active, as determined in coagulation or chromogenic assays, and all three activities were neutralized by monospecific antibodies. Vitamin K increased the quantity of prothrombin secreted by twofold, without affecting the rate of secretion over a five-day culture period, and had an apparent transient inhibitory effect on secretion of antithrombin III. Warfarin caused a three to fourfold decrease in the rate and quantity of secreted prothrombin, but did not affect intracellular concentrations. The intracellular and extracellular concentrations and rate of secretion of antithrombin III were not modulated by warfarin. These data suggest that the Hep G2 cell line may provide a useful model for assessing the regulation of biosynthesis and secretion of human coagulation proteins.

Antithrombin III↗

Antithrombin "Chicago": a functionally abnormal molecule with increased heparin affinity causing familial thrombophilia.

A family with a high incidence of spontaneous thromboembolism over four generations has been investigated. The propositus is a 21-yr-old male with a history of thrombophlebitis. Medical histories of 46 family members were obtained. Twelve of these individuals have experienced deep venous thromboses and/or pulmonary emboli. Seven members of the kindred, with a prior history of thrombotic phenomena, were investigated in detail. These subjects were found to have normal plasma concentrations of immunoreactive antithrombin (mean 96%), decreased plasma levels of progressive antithrombin activity (mean 50%), and greatly reduced amounts of plasma heparin cofactor activity (mean 42%). The abnormal antithrombin ("Chicago") was found to elute from heparin-Sepharose at a higher ionic strength than normal inhibitor. The functionally defective antithrombin molecules exhibit a reduced ability to neutralize thrombin in the presence or absence of heparin (approximately 10%-20% of normal). The molecular defect of this protease inhibitor thus appears to be distinct from those of previously described abnormal antithrombins.

Adult↗

A simple rate law that describes the kinetics of the heparin-catalyzed reaction between antithrombin III and thrombin.

The kinetics of the reaction between human thrombin and antithrombin III were studied in the presence of heparin fractionated according to its molecular size and affinity for antithrombin III. Reactions were monitored continuously through the loss of fluorescence intensity accompanying the displacement of the reversible inhibitor dansylarginine-N-(3-ethyl-1,5-pentanediyl)amide from thrombin upon its interaction with antithrombin III. As the concentration of heparin was increased in the presence of fixed concentrations of the two proteins, initial rates of the reaction increased up to a maximum and then decreased. Both the maximum rate and the concentration of heparin required to obtain a maximum increased with increased concentration of the proteins. The reaction appeared second order overall and first order with respect to each protein when heparin was in excess and zero order overall when the proteins were in excess. The existence of zero order kinetics at excess concentration of proteins indicates that the reaction is saturable in both proteins. The kinetics of the heparin-catalyzed reaction measured over an appreciable range of protein and heparin concentrations could be rationalized well by the simple rate equation, v = k X fa X fb X [H]t, where k is an intrinsic rate constant for the reaction between bound antithrombin III and thrombin, fa and fb are, respectively, the fractional saturation of available sites on heparin by antithrombin III and thrombin, and [H]t is the total concentration of heparin. This rate equation implies that interactions of both proteins with heparin are involved in the expression of catalytic activity through a template mechanism as proposed by M. W. Pomeranz and W. G. Owen ((1978) Biochim. Biophys. Acta 535, 66-77) and M. J. Griffith ((1982) J. Biol. Chem. 257, 7360-7365).

Antithrombin III↗

Decreased antithrombin III activity in diabetes may be due to non-enzymatic glycosylation--a preliminary report.

Antithrombin III activity was moderately but significantly decreased in insulin dependent diabetics (p less than 0.005), while no difference has been found between the diabetic (n = 25) and control groups (n = 22) in antithrombin III plasma concentration. Moreover, antithrombin III activity was inversely correlated with glycosylated plasma proteins (r = 0.57; p less than 0.01). These data show that in diabetes there is a depressed biological activity of antithrombin III and suggest that this reflects nonenzymatic glycosylation of antithrombin III protein.

Adult↗

Predictions of the secondary structure of antithrombin III and the location of the heparin-binding site.

The secondary structure of antithrombin III was investigated using the predictive scheme based on the amino acid sequence (Fasman, G. D., Chou, P. Y., and Adler, A. J. (1976) Biophys. J. 16, 1201-1238. The relative composition of the conformational regions is: 31% alpha-helix, 16% beta-sheet, 9% beta-turns, and the rest of the molecule in unordered conformation. When the alpha-helical regions are carefully delineated, 44% are predicted to be unstable helices because of unfavorable electrostatic interactions. Circular dichroism studies showed that the disruption of the first unfolding domain in antithrombin III by low concentration of guanidinium chloride (Villanueva, G. B., and Allen, N. (1983) J. Biol. Chem. 258, 14048-14053) was accompanied by a 42% decrease in the alpha-helical content. This suggested that the first unfolding domain demonstrated to be essential for heparin binding (Villanueva, G. B., and Allen, N. (1983) J. Biol. Chem. 258, 11010-11013) corresponds to the predicted unstable helical region. Model-binding studies of the unstable helical segment which contain tryptophan and lysine residues reveal that Lys-282, Lys-286, and Lys-289 are aligned on the same side of the alpha-helix. A model of the antithrombin III-binding octasaccharide (Lindahl, U., Backstrom, G., Thunberg, L., and Leder, I. G. (1980) Proc. Natl. Acad. Sci. U.S.A. 77, 6551-6555) was also constructed based on available NMR and x-ray data of the repeating units in heparin. These two models can be positioned such that the three lysine residues in the alpha-helix can be matched for maximal interaction with the three sulfate groups in the octasaccharide demonstrated as essential for binding antithrombin III. Based on these models, it is proposed that the unstable helical segment composed of residues 281-292 is the heparin-binding site in antithrombin III.

Amino Acid Sequence↗

[Effect of multiple intravenous injections of heparin on the content of antithrombin III in healthy animals and experimental atherosclerosis].

Content of antithrombin III in blood was decreased by 30-40% as compared with the initial level after eight intravenous injections of heparin (40 IU/200 g of body mass) into healthy rats and into animals with experimental atherosclerosis. The maximal decrease of antithrombin III content was found within 30 min after the last administration of heparin in circulation. Normalization of the antithrombin III occurred within 1.5-4 hrs after the heparin administration. Decrease in the content of antithrombin III after the heparin administration was accompanied by elevation in total fibrinolytic activity and in nonenzymatic fibrinolysis, thus indicating apparently the transient formation of heparin-blood proteins complexes including antithrombin III.

Animals↗

Involvement of heparin chain length in the heparin-catalyzed inhibition of thrombin by antithrombin III.

The mechanism of the heparin-promoted reaction of thrombin with antithrombin III was investigated by using covalent complexes of antithrombin III with either high-affinity heparin (Mr = 15,000) or heparin fragments having an average of 16 and 12 monosaccharide units (Mr = 4,300 and 3,200). The complexes inhibit thrombin in the manner of active site-directed, irreversible inhibitors: (Formula: see text) That is, the inhibition rate of the enzyme is saturable with respect to concentration of complexes. The values determined for Ki = (k-1 + k2)/k1 are 7 nM, 100 nM, and 6 microM when the Mr of the heparin moieties are 15,000, 4,300, 3,200, respectively, whereas k2 (2 S-1) is independent of the heparin chain length. The bimolecular rate constant k2/Ki for intact heparin is 3 X 10(8) M-1 S-1 and the corresponding second order rate constant k1 is 6.7 X 10(8) M-1 S-1, a value greater than that expected for a diffusion-controlled bimolecular reaction. The bimolecular rate constants for the complexes with heparin of Mr = 4,300 and 3,200 are, respectively, 2 X 10(7) M-1 S-1 and 3 X 10(5) M-1 S-1. Active site-blocked thrombin is an antagonist of covalent antithrombin III-heparin complexes: the effect is monophasic and half-maximum at 4 nM of antagonist against the complex with intact heparin, whereas the effect is weaker against complexes with heparin fragments and not monophasic. We conclude that virtually all of the activity of high affinity, high molecular weight heparin depends on binding both thrombin and antithrombin III to heparin, and that the exceptionally high activity of heparin results in part from the capacity of thrombin bound nonspecifically to heparin to diffuse in the dimension of the heparin chain towards bound antithrombin III. Increasing the chain length of heparin results in an increased reaction rate because of a higher probability of interaction between thrombin and heparin in solution.

Antithrombin III↗

Covalent complexes between low molecular weight heparin fragments and antithrombin III - inhibition kinetics and turnover parameters.

Two high affinity heparin fragments (Mr 4,300 and Mr 3,200) were covalently coupled to antithrombin III (J. Biol. Chem. 1982; 257: 3401--3408) with an apparent 1:1 stoichiometry and a 30--35% yield. The purified covalent complexes inhibited factor Xa with second order rate constants very similar to those obtained for antithrombin III saturated with these heparin fragments and to that obtained for the covalent complex between antithrombin III and native high affinity heparin. The disappearance rates from plasma in rabbits of both low molecular weight heparin fragments and their complexes could adequately be represented by two-compartment mammillary models. The plasma half-life (t1/2) of both low Mr-heparin fragments was approximately 2.4 hr. Covalent coupling of the fragments to antithrombin III increased this half-life about 3.5 fold (t1/2 congruent to 7.7 hr), approaching that of free antithrombin III (t1/2 congruent to 11 +/- 0.4 hr) and resulting in a 30 fold longer life time of factor Xa inhibitory activity in plasma as compared to that of free intact heparin (t1/2 congruent to 0.25 +/- 0.04 hr).

Antithrombin III↗

The antithrombin-binding sequence in heparin. Identification of an essential 6-O-sulfate group.

An octasaccharide with high affinity for antithrombin, isolated after partial deaminative cleavage of heparin, was previously found to have an L-iduronosyl-N-acetylglucosaminyl-6-O-sulfate nonreducing terminal disaccharide unit. After digestion of this octasaccharide with alpha-L-iduronidase and N-acetylglucosamine-6-sulfate sulfatase, two fractions, with high and low affinity for antithrombin, respectively, were isolated by affinity chromatography on antithrombin-Sepharose. Structural analysis showed that the high affinity fraction contained intact octasaccharide, whereas the low affinity fraction consisted of the expected heptasaccharide, lacking a 6-sulfate group on the terminal N-acetylglucosamine residue. Digestion of the octasaccharide with alpha-L-iduronidase only yielded heptasaccharide which was identical with the low affinity species except for the presence of this 6-sulfate group. This less degraded heptasaccharide retained high affinity for antithrombin. It is concluded that the 6-sulfate group on the N-acetylglucosamine residue is of critical importance to the interaction between heparin and antithrombin.

Animals↗

Demonstration of a two-domain structure of antithrombin III during its denaturation in guanidinium chloride.

The denaturation of human antithrombin III in urea and guanidinium chloride (GdmCl) was investigated by intrinsic fluorescence, circular dichroism, and absorption difference spectroscopy. Results suggest the existence of two structural domains as evidenced by the occurrence of two structural transitions, one at 0.7 M GdmCl and the other at 2.3 M GdmCl. This multistate unfolding transition has been confirmed under various protein concentrations and incubation times using different antithrombin III preparations, including a preparation that had been heated at 60 degrees C in the presence of 0.5 M citrate. The persistence of the multistate transition under these conditions rules out the possibilities that it could be due to the presence of different antithrombin populations in a mixture or the presence of a prosthetic group in the molecule. The first unfolding domain (0.7 M GdmCl) is stabilized by heparin and citrate. These protections suggest that the first unfolding domain of low stability may have functional relevance and important implications with respect to antithrombin III-heparin and antithrombin III-protease interaction.

Antithrombin III↗

Asymmetric distribution of sites with high affinity for antithrombin III in rat skin heparin proteoglycans.

The distribution of sites with high affinity for antithrombin III in [35S]heparin proteoglycans from rat skin was studied by affinity chromatography of the intact proteoglycans (Mr congruent to 1 x 10(6)) and degradation products. Unfractionated proteoglycan and proteoglycan fractions with low affinity and high affinity separated on antithrombin III-agarose were treated with alkali, releasing heparin chains (Mr congruent to 1 x 10(5)). Each chain preparation was fractionated on antithrombin III-agarose into fractions with low affinity and high affinity. Unfractionated proteoglycan and proteoglycan fractions with low affinity and high affinity were incubated with rat serum at pH 6.0, which gave products of similar size to commercial heparins (Mr congruent to 1 x 10(4)) termed heparin fragments. Each fragment preparation was fractionated on antithrombin III-agarose, yielding fractions with no affinity, low affinity, and high affinity, 40% of the proteoglycan preparation had low affinity, containing 4% high affinity chains and 7% high affinity fragments. The high affinity proteoglycan fraction yielded 40% high affinity chains and 22% high affinity fragments. The data show that the distribution of binding sites with high affinity for antithrombin III in heparin proteoglycans is highly asymmetric. Therefore, the concept that polymer modification reactions occurring during heparin biosynthesis, which must be involved in the formation of high affinity binding sites, occur in a random way must be reappraised.

Animals↗

Antithrombin III profiles in malignancy, relationship primary tumors and metastatic sites.

Variations of antithrombin III were studied in a non-randomized population of consecutive cancer cases admitted to a referral hospital. Differences between functional and immunologic assay were observed. Decreases were observed in both assays when compared to a population of hospitalized controls. Patients with cancer of the colon, ovary and prostate showed a deficiency of antithrombin III more frequently than other common tumors. When all tumor cases were subdivided into those in remission compared to those with metastases, a significant decrease in antithrombin III also could be shown. Metastases to the liver were strikingly common in cancer patients with decreased antithrombin III. In these patients, the decrease in antithrombin III could be statistically correlated with reduction in serum albumin.

Antithrombin III↗

[Prophylactic use of concentrated antithrombin III preparation in children with nephrotic syndrome].

Decreased plasma level of antithrombin III was assumed to be one of the major factors underlying hypercoagulable state in nephrotic syndrome. Concentrated antithrombin III preparation was given to 8 children with nephrotic syndrome with a plasma antithrombin III activity of less than 70%, to evaluate the effect on hypercoagulable state. Plasma antithrombin III activity was elevated to more than 70% in 7 of 8 children after treatment, while plasma levels of plasmin-alpha 2 plasmin inhibitor complex and FDP-D dimer were not significantly decreased. One patient developed brain infarction after the treatment, suggesting that prophylactic administration of concentrated antithrombin III preparation is not fully protective against thrombotic complications in nephrotic syndrome.

Adolescent↗

Complex-dependent inhibition of factor VIIa by antithrombin III and heparin.

The regulation of the factor VIIa-tissue factor complex is essential for control of the hemostatic response. However, the role of the inhibitor antithrombin III in the regulation of factor VIIa has remained in question. The inhibition of factor VIIa activity by antithrombin III and heparin in the presence and absence of tissue factor was evaluated using the fluorescent substrate m-LGR-nds. Our data show that the activity of recombinant human factor VIIa is inhibited by antithrombin III in the presence of heparin at a rate of 1.7 x 10(2) M-1 s-1. In the presence of tissue factor, the rate constant for this reaction increases to 5.6 x 10(3) M-1 s-1. A 1:1 stoichiometric complex between factor VIIa and antithrombin III, with an apparent molecular weight of 110,000, was detected by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. A heterogeneous mixture of factor VIIa products with molecular weights between 50,000 and 80,000, most likely representing proteolytically degraded factor VIIa-antithrombin III complexes, was also observed.

Antithrombin III↗

Circadian rhythms of fibrinogen and antithrombin III in liver cirrhosis.

BACKGROUND: Since acquired deficiencies of fibrinogen and antithrombin III are reported in liver cirrhosis and it is known that their plasma levels fluctuate during the day, the circadian rhythms of plasma fibrinogen and plasma antithrombin III were investigated in patients with compensated and decompensated cirrhosis, compared to healthy controls. METHODS: Three groups of subject were considered: (A) 10 healthy controls; (B) 10 patients with compensated liver cirrhosis; (C) 10 patients with decompensated liver cirrhosis. The fibrinogen and antithrombin III levels were determined in blood samples drawn in each studied subject during the span of a whole day and every three hours starting from midnight. The time-related data were analyzed by means of the "mean-group cosinor" method. RESULTS: Significant (p < 0.05) circadian rhythms were detected for the two variables in groups A and B, with peaks in the afternoon hours. No significant (p > 0.05) rhythms were found for group C. A significant (p < 0.05) difference was found between the three groups regarding the circadian rhythm of fibrinogen, and between controls and patients with compensated cirrhosis and between compensated and decompensated patients regarding the circadian rhythm of antithrombin III. CONCLUSIONS: These data suggest that in healthy subjects the plasma levels of fibrinogen and antithrombin III present daily variations with own circadian rhythms, and that liver cirrhosis is associated with chronobiological circadian changes in the coagulation system, related to the stage of the disease. This progressive derangement could be considered as an index of evolution in the natural history of cirrhosis of the liver.

Antithrombin III↗

Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview.

CONTEXT: Antithrombin therapy has become a guidelines-recommended standard of care in the treatment of acute coronary syndromes (ACS), but recent trials comparing use of enoxaparin and unfractionated heparin in ACS have yielded less robust efficacy and safety results than have earlier trials of these antithrombin therapies. OBJECTIVE: To systematically evaluate the end points of all-cause death and nonfatal myocardial infarction (MI), transfusion, and major bleeding observed in the 6 randomized controlled trials comparing enoxaparin and unfractionated heparin in treatment of ACS. DATA SOURCES: The primary data sets for ESSENCE, A to Z, and SYNERGY were available at the Duke Clinical Research Institute. Baseline characteristics and event frequencies for TIMI 11B, ACUTE II, and INTERACT were provided by the principal investigator of each study. STUDY SELECTION: All 6 randomized controlled trials comparing enoxaparin and unfractionated heparin in non-ST-segment elevation ACS were selected for analysis. DATA EXTRACTION: Efficacy and safety end points were extracted from the overall trial populations and the subpopulation receiving no antithrombin therapy prior to randomization. DATA SYNTHESIS: Systematic evaluation of the outcomes for 21 946 patients was performed using a random-effects empirical Bayes model. No significant difference was found in death at 30 days for enoxaparin vs unfractionated heparin (3.0% vs 3.0%; odds ratio [OR], 1.00; 95% confidence interval [CI], 0.85-1.17). A statistically significant reduction in the combined end point of death or nonfatal MI at 30 days was observed for enoxaparin vs unfractionated heparin in the overall trial populations (10.1% vs 11.0%; OR, 0.91; 95% CI, 0.83-0.99; number needed to treat, 107). A statistically significant reduction in the combined end point of death or MI at 30 days was also observed for enoxaparin in the populations receiving no prerandomization antithrombin therapy (8.0% vs 9.4%; OR, 0.81; 95% CI, 0.70-0.94; number needed to treat, 72). No significant difference was found in blood transfusion (OR, 1.01; 95% CI, 0.89-1.14) or major bleeding (OR, 1.04; 95% CI, 0.83-1.30) at 7 days after randomization in the overall safety population or in the population of patients receiving no prerandomization antithrombin therapy. CONCLUSION: In a systematic overview of approximately 22 000 patients across the spectrum of ACS, enoxaparin is more effective than unfractionated heparin in preventing the combined end point of death or MI.

Angina Pectoris↗